- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical
Evelo Biosciences, Inc.: Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis physician-reported outcomes -
-Improvements in patient-reported outcomes in DLQI and POEM, including itch-
-EASI50 benchmark reached in 44% of patients treated with EDP1815 compared to 0% in placebo group at day 70-
-Phase 2 atopic dermatitis trial initiation in 3Q 2021-
-Management to host conference call at 8:30 a.m. ET today with Dr. Benjamin Ehst-
CAMBRIDGE, Mass., Jan. 20, 2021interim data in 23 evaluable patients. These new results now include patient-reported outcomes, as well as all of the physician-reported outcomes for all 24 patients in the cohort. The primary endpoint of the Phase 1b trial was safety and tolerability. EDP1815 was well tolerated in this study with no treatment-related adverse events of moderate or severe intensity, and no serious adverse events.